

5/13/2025

Village Farms International (VFF)

Company update: Overweight

US\$Mn								
Cons Rev	CY23a	CY24a	CY25e	Prev	CY26e	Prev	CY27e	Prev
1Q	64.7	78.1	73.1	76.5	86.7	82.8	94.7	88.7
2Q	77.2	92.2	86.8	88.6	100.8	95.1	108.8	100.9
3Q	69.5	83.4	88.9	88.9	99.9	94.1	109.8	100.3
4Q	74.2	82,6	92.8	89.8	101.8	91.5	105.7	88.7
FY	285.6	336.2	341.6	343.8	389.2	363.5	419.1	378.6
EBITDA	CY23a	CY24a	CY25e	Prev	CY26e	Prev	CY27e	Prev
1Q	0.5	3.6	2.9	4.8	8.6	8.8	12.1	10.1
2Q	4.5	-3.6	-3.2	-2,2	8.9	7.9	12.1	9.2
3Q	3.2	5.3	0.8	8.1	12.6	10.2	15.7	11.7
4Q	-0.7	-3.5	8.4	8.7	<u>14.5</u>	10.5	16.6	10.2
FY	7.6	1.8	16.1	19.4	44.5	37.4	56.5	41.2
Share price	e (US\$)	0.73	Perf.	VFF	YOLO ETF	\$&P500	Stance:	Overweight
Share cour	nt (mn)	112.3	30d	16%	7%	0%		no price target
Market Cap	p (US\$Mn)	82	90d	1%	-15%	-8%		FY=Dec
Ticker		VFF	1yr	-46%	-49%	9%		
· School or Street	hu. (777-125) 100000-108 40 07	C D COLOR COLOR CO.		No. 10.000 - No. 90,000 - Outp	US\$Mn	CY24	CY25	CY26
COLUMN TORNING				100	Projected EV	113	115	91
_ ^ / \ \				10.00	EV/Sales	0.3x	0.3x	0.2x
MILLI		IM			EV/EBITDA	63.4x	7.1x	2.0x
Ly 1	1	16 5	Λ	0.00				
	J 1 1	W L A	V M	855		CY24	CY25	CY26
	DIV	AT W	\ _\		Net debt/Sales	-0.1x	-0.1x	na
	00		N Vh	w 🗖	Net debt/EBITDA	-11.1x	-1.3x	na
			14	1.00	Free Cash Flow	0.3	-1.2	24.1
			V \	1105	Net (debt) cash	-19.9	-21.1	2.9
	the III	1.1	7.V					
to all a		6117	1 Vh	48	Consensus		CY25	CY26
الالبيا		414	والرابط		Sales		349.6	373.9
				4	EBITDA		20.0	24.4
2 30 0	0 9 9	ne or	* > n/4	. "	Guidance CY25:		n/a	
ACTSET - THE PARTY NAMED IN	e futuration		ats of the	me 16, 2023 to 1020 detectors				

Pablo Zuanic

ZUANIC & ASSOCIATES pablo.zuanic@zuanicgroup.com 420Odysseus; www.zuanicassociates.com



On 1Q25 Results, Outlook, and Produce Spin

We rate VFF Overweight. By privatizing part of its produce assets (a portion accounting for 85% of produce revenue, but a source of distraction and volatile EBITDA), for a \$40Mn cash inflow (note the VFF market cap yesterday was \$79Mn) plus a 38% equity stake in a new external entity, while keeping US optionality, the valuation case in VFF becomes even more compelling. Taking proforma math, VFF now trades at 0.4x current consolidated sales and 3.6x EBITDA. We do not set price targets, but at 1x sales (more in line with comparable peers), the stock would more than 2x. Investors should focus on the strength of the VFF domestic rec cannabis business (lowest production costs; top3 in sales), MMJ export growth, Holland rec upside, plus future US optionality. VFF is a NASDAQ-listed cannabis company with what we see as a sustainable and disciplined financial model. For greater context, see our 4/30 note on VFF. Note: All numbers in US\$ unless otherwise.

On 4Q results.

- Cannabis exports were up 3x seq to C\$7.7Mn (Australia, Germany, UK, were noted); B2B remained strong at C\$9Mn (in the past, management has said about a third of this is reexported by local buyers); branded rec fell 7% seq to C\$33Mn (down 17% yoy) given increased focus on profit margins (it was still #3 in Canada). The better sales mix was reflected in an 11pt yoy jump in gross margins to 36% (moving back to the higher end of the 30% to 40% target range), and EBITDA margins of 19% (vs. 11% the year before).
- Leli began to report sales (US\$486K was in line with our estimate), and reported positive segment EBITDA (\$77K vs. -\$259K in 4Q24); gross margins came in at 41%.
- US CBD/hemp sales fell 15% seq to \$3.9Mn, while gross margins remained in the upper 60s (66.4% in 1Q25). EBITDA was near break-even at \$114K (3% of sales)
- 1Q is a seasonal low qtr for produce. Sales of \$37Mn were up 4% (more volume from supply partners), but gross margins fell to -11% from +9% in 1Q24; EBITDA came in at -\$5Mn vs. +\$2Mn in 1Q24. Higher costs due to the impact of dust storms impacting a TX facility explain the lower margins (there is also an early accounting cost recognition given lower yields for the crop ending Jun'25).
- Corporate expenses remained in the \$2Mn range. The drop in consolidated EBITDA to +0.1% from +4.6% a year ago is explained by the poor results in produce.

Forward comments.

- It continues to expect cannabis exports to 3x from te CY24 base of US\$6.1M.
- Phase II in the Netherlands (facility in Groningen) is expected to be completed by 1Q26 (5x capacity).
- Application for an MMJ license in TX remains pending review.



BHB now makes all its hemp-derived gummies in house.

On the (partial) produce spin. VFF will transfer part of its US produce assets to an external entity (Vanguard Food), in which it will own a 38% stake, and it will receive a \$40Mn cash payment (for context, at close yesterday the VFF total market cap was \$74Mn). VFF will retain control of the Canadian produce assets, which generated \$25Mn in produce sales in CY24 (of a total of \$169Mn). So, the bulk of the revenue generating US assets will be transferred to the new entity. Overall, per management, the transaction will allow for increased VFF focus on the cannabis business, generate upside from the externally managed new entity's roll-up strategy, while also retaining US cannabis optionality from the TX greenhouses. Highlights,

- VFF will privatize its Texas-based, 40-acre Marfa II and 40-acre Fort Davis greenhouse assets, plus all of its produce-related intellectual property, with the exception of the Village Farms name, and transfer all of its produce distribution facilities, employees and operational control of these facilities to Vanguard.
- Upon completion of the transaction, VFF will continue to own its 30-acre Monahans greenhouse facility in Texas, and it will own and lease its 20-acre Marfa I greenhouse facility in Texas to Vanguard. The Marfa I facility is currently expandable to 40-acres and is adjacent to 950 acres of unoccupied land owned by Village Farms available for future expansion ("retaining significant long-term optionality for potential future cannabis expansion in the US").
- In Canada, Village Farms will continue to own and operate its 60-acre Delta 1 greenhouse, 25-acre Delta 2 greenhouse, and 25-acre Delta 3 greenhouse, each of which are located in Delta, British Columbia. Village Farms will enter into service and supply agreements with Vanguard for fresh produce production in Delta, which will continue supplying produce for Vanguard for a multi-year term. The Delta 1 greenhouse generated ~\$25Mn in fresh produce sales in fiscal year 2024.
- Village Farms is expected to receive \$40 million in cash proceeds, as well as a 37.9% equity
 ownership interest in Vanguard upon closing of the transaction, which is expected to
 occur during the second quarter of 2025. Vanguard is expected to be backstopped by
 additional capital commitments to execute a M&A roll-up strategy of other produce
 brands and assets in North America.
- Our proforma math: Produce sales drop to \$25Mn from \$169Mn (taking CY24 numbers); cash goes up by \$40Mn; VFF has now a 38% equity stake in an external company (book value to be determined).

Valuation. After the close yesterday, the VFF EV was US\$113Mn (113mn shares including RSUs; net debt of \$29Mn; \$10Mn in redeemable non-controlling interest; \$3Mn in leases net of right of use assets). Now, with the \$40Mn cash inflow the EV is \$73Mn. The consolidated sales base taking 1Q25 annualized (\$77Mn x 4) minus the \$144Mn span out produce revenue (\$169Mn - \$25Mn) is \$164Mn. So, the new proforma EV/sales multiple is 0.4x. If we take out the produce EBITDA, the new proforma EBITDA is around \$20Mn (\$5Mn x 4), so VFF trades at 3.6x. We see the valuation as



compelling given the strength of the company's domestic rec business, export growth, Lei upside, plus future US optionality (and not factoring the value of the stake in Vanguard Food). Investors here can buy a leading cannabis producer (one with a sustainable and disciplined financial model, the lowest production costs, and international optionality) at a compelling valuation – and one that is NASDAQ listed. Note: Per a NASDAQ notification, with VFF shares trading below US\$1, the company has until 10/16/25 (factoring a recent 180-day extension) to regain compliance with the NASDAQ "minimum bid requirement".

Table 1: Companies mentioned in this report.

Company name	Ticker	Ticker	Rating
US MSOs			
4Front Ventures		FENTE	not rated
Ascend Wellness		AAWH	will cover
AYR Wellness		AYRWF	not rated
Cannabist		CCHWF	not rated
Cansortium		CNTMF	not rated
Cresco Labs		CRLBF	Overweight
Curaleaf Holdings		CURLF	will cover
GlassHouse Brands		GLASF	not rated
Gold Flora		GRAM	Overweight
Green Thumb Industries		GTBIF	Overweight
Grown Rogue		GRUSE	not rated
Jushi Holdings		JU S HF	Overweight
MariMed		MRMD	Overweight
Planet 13 Holdings		PLNHF	Overweight
Schwazze		SHWZ	not rated
TerrAscend		TSNDF	will cover
TILT Holdings		TLLTF	Neutral
Trulieve Cannabis		TCNNF	will cover
Verano Holdings		VRNOF	Overweight
Vext Science, Inc.		VEXTF	Overweight
Vireo Growth		VREOF	will cover
Finance (MJ) Companies			
AFC Gamma		AFCG	Overweight
Chicago Atlantic BDC		LIEN	will cover
Chicago Atlantic REAF		REFI	Overweight
Innovative Industrial Prop	perties	IIPR	will cover
New Lake Capital Partners	i.	NLCP	Overweight
SHF Holdings		SHFS	not rated

V V		
Company name	Ticker	Rating
Canada LPs		
Aurora Cannabis	ACB	Neutral
Auxty Cannabis Group	CBWTF	not rated
Avant Brands	AVTBF	not rated
Avicanna	AVCN	not rated
Ayurcann Holdings	AYURF	not rated
Cannara Biotech	LOVFF	not rated
Canopy Growth Corporation	CGC	will cover
Cronos Group	CRON	not rated
Decibel Cannabis Co	DBCCF	Overweight
Organigram Holdings	OGI	not rated
Rubicon Organics	ROMJF	will cover
SNDL	SNDL	not rated
Tilray Brands	TLRY	Neutral
Village Farms Intl	VFF	Overweight
Other		
Agrify	AGFY	not rated
Cannapresso	TBD	not rated
Canto urage AG	HIGH:FF	not rated
Flora Growth	FLGC	not rated
Grow Generation	GRWG	not rated
Intercure	INCR	not rated
Ispire Technology	ISPR	will cover
Leafly	LFLY	not rated
LFTD Partners Inc.	LIFD	Overweight
Smoore International	SMORF	will cover
Springbig	SBIG	not rated
Urban-gro	UGRO	not rated
WM Technology	MAP5	Neutral

Source: Z&A



Appendix I: Company Financials



Exhibit 1: Consolidated Highlights (not factoring produce spin)

US\$Mn	CY22	CY23	1Q24	2Q24	3Q24	4Q24	CY24	1Q25	2Q25e	3Q25e	4Q25e	CY25e	CY26e	CY27e
Proforma consolidated sales	293.6	285.6	78.1	92.2	83.4	82.6	336.2	77.1	86.0	86.8	89.1	339.0	387.2	417.0
gog ch %	na	na	5%	18%	-10%	-1%	na	-7%	12%	1%	3%	na	na	na
yoy ch %	10%	-3%	21%	19%	20%	11%	18%	-1%	-7%	4%	8%	1%	14%	8%
quidance		na					na					na	na	na
consensus								78.4	90.1	90.1	93.8	349.6	373.9	na
Profit margins														
Gross profit after FV adj	27.5	49.4	15.5	9.2	15.7	6.9	47.4	11.3	10.2	20.3	20.0	61.9	101.2	116.6
as % of sales	9.4%	17.3%	19.9%	10.0%	18.8%	8.4%	14.1%	14.7%	11.9%	23.4%	22.5%	18.3%	26.1%	28.0%
Ор ехр	72.3	65.5	16.4	19.7	16.5	18.5	71.0	16.8	18.1	17.7	17.8	70.4	77.9	82.0
as % of sales	24.6%	22.9%	21.0%	21.3%	19.8%	22.4%	21.1%	21.8%	21.1%	20.4%	20.0%	20.8%	20.1%	19.7%
EBIT	-44.8	-16.1	-0.9	-10.4	-0.8	-11.5	-23.6	-5.4	-7.9	2.6	2.2	-8.5	23.3	34.7
as % of sales	-15.2%	-5.6%	-1.1%	-11.3%	-1.0%	-14.0%	-7.0%	-7.1%	-9.2%	3.0%	2.5%	-2.5%	6.0%	8.3%
Adj EBITDA	-21.3	7.6	3.6	-3.6	5.3	-3.5	1.8	0.1	-3.7	6.9	6.5	9.8	40.7	52.5
as % of sales	-7.3%	2.7%	4.6%	-3.9%	6.4%	-4.3%	0.5%	0.1%	-4.3%	7.9%	7.3%	2.9%	10.5%	12.6%
consensus								3.0	2.5	6.5	7.5	20.0	24.4	na
as % of sales								3.9%	2.7%	7.2%	8.0%	5.7%	6.5%	na
EPS														
Pre taxincome	-96.7	-27.4	-2.4	-23.3	-0.7	-11.0	-37.3	-6.1	-8.6	1.8	1.3	-11.6	-2.7	5.4
Tax rate assumption	-4.8%	-16.3%	-13.6%	-1.1%	-14.3%	21.3%	4.5%	-16.0%	20.0%	20.0%	20.0%	1.0%	20.0%	20.0%
Netincome	-101.4	-31.8	-2.7	-23.6	-0.8	-8.7	-35.6	-7.1	-6.9	1.4	1.1	-11.5	-2.1	4.3
Share count (FD) Mn	89.1	108.7	110.2	111.0	111.9	112.4	111.4	112.3	112.3	112.3	112.3	112.3	112.3	112.3
EPS	-1.13	-0.29	-0.03	-0.21	-0.01	-0.08	-0.32	-0.06	-0.08	-0.01	-0.01	-0.16	-0.09	-0.03
consensus								-0.02	-0.02	0.02	0.02	0.00	0.04	na
BS & CF highlights														
Operating cash flow	-19.9	5.3	-0.1	-7.0	17.0	0.4	10.3	-6.4	-12.5	0.7	-0.4	-18.6	-8.5	4.5
(-) Capex	-14.3	-6.5	-1.9	-3.0	-3.3	-1.9	-10.1	-2.5	-2.6	-2.6	-2.7	-10.4	-8.5	-9.2
Free cash flow	-34.2	-1.2	-1.9	-10.0	13.7	-1.5	0.3	-8.9	-15.1	-1.9	-3.1	-29.0	-17.0	-4.6
Ending net cash (debt)	-39.3	-16.8	-18.4	-18.8	-18.6	-19.9	-19.9	-29.1	-44.2	-46.1	-49.2	-49.2	-416.8	-413.0
Net debt/Sales	-0.1x	-0.1x	-0.1x	-0.1x	-0.1x	-1.1x	-1.0x							
Net debt/EBITDA	1.8x	-2.2x	-1.3x	1.3x	-0.9x	1.4x	-11.1x	-89.7x	3.0x	-1.7x	-1.9x	-5.0x	-10.2x	-7.9x
Equity	303.1	302.6	296.2	275.2	274.4	254.0	254.0	248.3	239.1	238.3	237.2	237.2	226.6	223.3

Source: Z&A estimates, company reports



Exhibit 2: Divisional Split

US\$Mn	CY22	CY23	1Q24	2Q24	3Q24	4Q24	CY24	1Q25	2Q25e	3Q25e	4Q25e	CY25e	CY26e	CY27e
Sales	293.6	285.6	78.1	92.2	83.4	82.6	336.2	77.1	86.0	86.8	89.1	339.0	387.2	417.0
Produce	160.3	151.2	36.1	47.0	42.8	43.3	169.2	37.4	47.5	43.2	43.7	171.8	173.6	175.3
Cannabis PSF	109.9	114.0	37.4	40.7	36.5	34.2	148.9	34.8	33.5	38.0	39.7	146.0	169.2	188.2
US CBD/Hemp	23.3	20.3	4.5	4.3	3.9	4.6	17.4	3.9	3.9	3.9	4.0	15.7	16.1	16.4
Energy	0.1	0.0	0.0	0.1	0.2	0.4	0.8	0.4	0.3	0.3	0.3	1.3	1.2	1.2
Leli Holland								0.5	0.8	1.3	1.5	4.1	27.2	35.9
Gross Margin	9.4%	17.3%	19.9%	10.0%	18.8%	8.4%	14.1%	14.7%	11.9%	23.4%	22.5%	18.3%	26.1%	28.0%
Produce	-10.8%	0.1%	9.2%	-8.9%	8.1%	5.6%	3.0%	-11.4%	-8.8%	8.2%	5.7%	-1.4%	5.5%	5.5%
Cannabis PSF	26.7%	31.5%	25.4%	26.3%	26.3%	2.5%	20.6%	35.8%	35.8%	37.2%	38.7%	36.9%	41.0%	42.1%
US CBD/Hemp	67.2%	65.6%	59.4%	61.2%	63.4%	69.6%	63.5%	66.4%	60.0%	60.0%	60.0%	61.6%	60.0%	60.0%
Energy	na	na	na	na	na	na	na	na	na	na	na	na	na	na
Leli Holland								41.4%	25.0%	30.0%	35.0%	32.1%	46.7%	50.0%
EBITDA	-21.3	7.6	3.6	-3.6	5.3	-3.3	2.0	0.1	-3.9	6.9	6.6	9.6	51.8	68.8
Produce	-24.4	0.5	2.0	-6.4	2.3	4.1	2.2	-5.1	-5.4	2.6	1.5	-6.4	5.7	5.8
Cannabis PSF	13.1	14.8	4.1	4.8	4.8	-6.4	7.3	6.7	6.7	8.9	10.1	32.4	42.9	50.0
US CBD/Hemp	0.2	0.9	-0.6	-0.2	-0.3	0.5	-0.7	0.1	-0.6	-0.6	-0.6	-1.8	-2.3	-2.1
Energy	-0.3	-0.2	0.0	0.1	0.3	0.4	0.8	0.3	0.0	0.0	0.0	0.2	-0.1	-0.1
Leli Holland								0.1	-0.3	0.0	0.1	-0.1	11.1	16.4
Corporate	-10.0	-8.4	-1.8	-1.8	-1.9	-1.9	-7.5	-2.0	-4.3	-4.0	-4.5	-14.8	-5.5	-1.2
EBITDA margin	-7.3%	2.7%	4.7%	-3.9%	6.3%	-4.0%	0.6%	0.1%	-4.6%	7.9%	7.4%	2.8%	13.4%	16.5%
Produce	-15.2%	0.3%	5.6%	-13.5%	5.5%	9.6%	1.3%	-13.7%	-11.3%	6.0%	3.5%	-3.7%	3.3%	3.3%
Cannabis PSF	11.9%	12.9%	10.9%	11.8%	13.0%	-18.6%	4.9%	19.2%	20.0%	23.3%	25.5%	22.2%	25.4%	26.6%
US CBD/Hemp	1.0%	4.2%	-13.6%	-5.6%	-7.0%	10.0%	-3.9%	2.9%	-16.2%	-15.8%	-15.4%	-11.2%	-14.5%	-12.9%
Energy	na	na	na	na	na	na	na	na	na	na	na	na	na	na
Leli Holland								15.8%	-33.4%	0.3%	7.9%	-1.8%	40.8%	45.5%
Corp as % of total sales	-3.4%	-2.9%	-2.3%	-2.0%	-2.2%	-2.4%	-2.2%	-2.6%	-5.0%	-4.6%	-5.1%	-4.4%	-1.4%	-0.3%

Source: Z&A estimates, company reports



Exhibit 3: Cannabis Projections

US\$Mn	CY22	CY23	1Q24	2Q24	3Q24	4Q24	CY24	1Q25	2Q25e	3Q25e	4Q25e	CY25e	CY26e	CY27
Sales (ex Leli)	107.2	112.0	37.0	40.3	40.2	40.3	157.8	33.4	33.5	38.0	39.7	144.5	169.2	188.2
Canada cannabis	103.4	107.4	35.5	38.8	38.9	38.5	151.7	28.0	28.5	32.5	33.7	122.8	132.7	139.4
branded	85.5	91.9	29.0	30.5	32.4	32.5	124.5	24.5	24.7	28.3	29.5	107.1	116.1	121.9
bulk	17.8	15.5	6.5	8.3	6.5	6.0	27.2	3.5	3.8	4.2	4.2	15.7	16.6	17.4
International	3.9	4.6	1.5	1.5	1.4	1.8	6.1	5.4	5.0	5.5	5.9	21.8	36.5	48.8
Cannabis P&L														
Sales	107.2	112.0	37.0	40.3	40.2	40.3	157.8	33.4	33.5	38.0	39.7	144.5	169.2	188.2
qoq ch %	na	na	17%	9%	0%	0%	na	-17%	0%	13%	4%	na	na	na
yoy ch %	11%	4%	47%	44%	42%	28%	41%	-10%	-17%	-6%	-2%	-8%	17%	11%
Gross profit	29.4	35.9	9.5	10.7	9.6	0.9	30.7	12.5	12.0	14.1	15.4	53.9	69.4	79.3
as % of sales	27.4%	32.1%	25.7%	26.6%	23.9%	2.2%	19.4%	37.4%	35.8%	37.2%	38.7%	37.3%	41.0%	42.1%
EBIT	-2.2	4.5	1.8	1.7	1.6	1.9	-4.4	3.7	4.5	6.6	7.9	22.7	33.8	40.7
as % of sales	-2.1%	4.0%	4.9%	4.2%	4.0%	4.8%	-2.8%	11.1%	13.4%	17.4%	19.8%	15.7%	20.0%	21.6%
EBITDA	13.1	14.8	4.1	4.8	4.8	-6.4	7.3	6.7	6.7	8.9	10.1	32.4	42.9	50.0
as % of sales	12.2%	13.2%	11.0%	12.0%	11.8%	-15.8%	4.6%	20.1%	20.0%	23.3%	25.5%	22.4%	25.4%	26.6%
Branded rec assumptions														
Canada rec market (C\$Mn)	4,518	5,163	1,196	1,258	1,380	1,396	5,230	1,255	1,321	1,449	1,466	5,491	5,766	6,054
Canada rec market (US\$Mn)	3,470	3,826	887	919	1,012	998	3,816	875	950	1,042	1,055	3,922	4,147	4,355
wholesale adj for 0.4x fac	1,388	1,531	355	368	405	399	1,526	350	380	417	422	1,569	1,659	1,742
PSF branded sales US\$Mn	85.5	91.9	29.0	30.5	32.4	32.5	124.5	24.5	24.7	28.3	29.5	107.1	116.1	121.9
in C\$Mn	112.2	124.0	39.1	41.8	44.2	45.5	170.4	35.2	34.3	39.4	41.1	150.0	161.4	169.5
share %	6.2%	6.0%	8.2%	8.3%	8.0%	8.1%	8.2%	7.0%	6.5%	6.8%	7.0%	6.8%	7.0%	7.0%
PSF reported yoy C\$ sales gr	25%	11%	37%	31%	43%	34%	37%	na						
Growth per Hifyre		9%	21%	40%	22%	-1%	20%	-19%	na	na	na	na	na	na
Reported sales / Retail sales per l	Hifvre	36%	38%	37%	42%	51%	42%	na						

(*) in practice, this may be more in the low/mid 30s.

Source: Z&A estimates, Hifyre, StatCan, company reports



Exhibit 4: Cash Flow

IS\$ 000s														
UMMARY CASH FLOW	CY22	CY23	1Q24	2Q24	3Q24	4Q24	CY24	1Q25	2Q25e	3Q25e	4Q25e	CY25e	CY26e	CY27€
Net earnings	-101,146	-31,798	-2,852	-23,549	-820	-8,422	-35,643	-7,115	-9,215	-826	-1,135	-18,291	-10,520	-3,318
(+) D&A	13,054	15,926	4,558	4,840	5,109	4,331	18,838	4,973	4,224	4,251	4,278	17,727	17,405	17,774
Cash earnings	-88,092	-15,872	1,706	-18,709	4,289	-4,091	-16,805	-2,142	-4,990	3,425	3,143	-565	6,886	14,456
(-) Working capital chang	-2,246	-2,088	-3,290	-3,109	11,701	-4,864	438	-4,209	-5,225	-448	-1,376	-11,257	-6,965	-2,258
(-) Other operating flows	70,449	23,275	1,534	14,799	1,015	9,367	26,715	-25	-2,302	-2,257	-2,212	-6,796	-8,392	-7,660
Net operating cash flow	-19,889	5,315	-50	-7,019	17,005	412	10,348	-6,376	-12,517	720	-445	-18,618	-8,472	4,537
(-) net capex	-14,292	-6,518	-1,876	-3,003	-3,268	-1,936	-10,083	-2,539	-2,581	-2,604	-2,674	-10,398	-8,519	-9,174
Free cash flow	-34,181	-1,203	-1,926	-10,022	13,737	-1,524	265	-8,915	-15,098	-1,884	-3,119	-29,015	-16,990	-4,637
(-) acquisitions	-5,873	0	0	-3,096	-80	0	0	0	0	0	0	0	0	0
(-) divestitures	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(+) other	4,778	-1,099	295	12,754	-13,452	150	-3,429	-232	0	0	0	-232	-350,675	8,492
(+) share issuance/repur	6,692	24,772	0	0	0	0	0	0	0	0	0	0	0	0
(-) stock options/warrant	192	83	0	0	0	0	0	0	0	0	0	0	0	0
Change in net	-28,392	22,553	-1,631	-364	205	-1,374	-3,164	-9,147	-15,098	-1,884	-3,119	-29,247	-367,666	3,856
	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ending net (debt)	-39,320	-16,767	-18,398	-18,762	-18,557	-19,931	-19,931	-29,078	-44,176	-46,059	-49,178	-49,178	-416,844	-412,988
Cash/inv/sec	21,676	35,291	31,685	29,657	28,696	24,631	24,631	15,125	3,000	3,000	3,000	3,000	3,000	3,000
Gross debts/loans/bor	60,996	52,058	50,083	48,419	47,253	44,562	44,562	44,203	47,176	49,059	52,178	52,178	419,844	415,988
Net debt / Sales	-0.1x	-0.1x	-0.1x	-0.1x	-0.1x	-0.1x	-0.1x	-0.1x	-0.1x	-0.1x	-0.1x	-0.1x	-1.1x	-1.0x
Net debt / Adj EBITDA	1.1x	-2.2x	-1.3x	1.3x	-0.9x	1.4x	-11.1x	-89.7x	3.0x	-1.7x	-1.9x	-5.0x	-10.2x	-7.9x

Source: Z&A estimates, company reports



Appendix II: Valuation Comps



Exhibit 5: Canada LPs - Valuation Multiples (consolidated multiples; not factoring VFF produce spin)

								<u>Financial</u>	Net Debt				
Multiples	Z&A 9	Spot EV / S	<u>Sales</u>	<u> Z&A S</u>	pot EV / El	BITDA	to Sa	ales	to EB	<u>ITDA</u>	<u>Sto</u>	ck Perform	ance_
13-May-25	Current	2025	2026	Current	2025	2026	Current	CY25	Current	CY25	30-day	90-day	1-year
Aurora Cannabis	1.2x	1.2x	1.1x	4.7x	6.6x	5.9x	na	na	na	na	18%	-21%	-22%
Auxly Cannabis Group	1.6x	na	na	11.0x	na	na	-0.3x	na	-2.2x	na	-8%	-23%	-63%
Avant Brands	0.6x	na	na	2.9x	na	na	-0.1x	na	-0.6x	na	12%	65%	47%
Cannara Biotech	1.5x	na	na	6.4x	na	na	-0.4x	na	-1.8x	na	-1%	8%	50%
Canopy Growth	1.9x	2.0x	1.8x	-40.3x	400.3x	97.5x	-0.7x	-0.7x	14.7x	-146.1x	55%	-19%	-84%
Cronos Group	-2.4x	-2.1x	-1.9x	-1.2x	-121.3x	na	na	na	na	na	17%	4%	-26%
Decibel Cannabis	0.7x	0.6x	0.5x	3.5x	3.0x	2.5x	-0.3x	-0.3x	-1.5x	-1.3x	22%	-11%	-37%
Organigram Holdings	1.2x	0.8x	0.7x	-56.7x	10.4x	6.4x	na	S	na	na	24%	-11%	-27%
Rubicon Organics	0.6x	na	na	5.5x	na	na	0.0x	na	0.0x	na	-20%	11%	21%
SNDL	0.3x	0.3x	0.3x	14.2x	17.8x	na	na	na	na	na	-3%	-27%	-43%
Tilray Brands	0.7x	0.6x	0.6x	15.1x	7.4x	6.1x	0.0x	0.0x	-0.8x	-0.4x	-6%	-51%	-76%
Village Farms Internatio	0.3x	0.3x	0.3x	-7.8x	5.8x	3.6x	-0.1x	-0.1x	1.4x	-1.0x	40%	-10%	-44%

¹⁾ We take FactSet consensus estimates for CY25e and CY26e, if available; 2) By "current", we mean the latest reported qtr annualized; 3) several LPs have net cash Source: FactSet and company reports



Exhibit 6: Canada LPs - EV Calculations

FactSet Spot EV	Z&A Spot EV	C\$ price	mn shares	mn deriv	Total Mkt Cap	Financial net debt	Net leases	ST income tax liab.	Conting Cons.	ITM deriv	Total BDND	Pref Stock Min Int
345	437	7.05	54.9	1.2	395	51	-43		-10		-2	39
233	181	0.09	1,285.7	133.4	128	-36	-14		-2		-52	
244	26	0.90	10.6	0.2	10	-6	-10				-16	
85	153	1.21	90.0	0.0	109	-43	0	-1			-44	
na	560	2.03	173.4	1.4	355	-204					-204	
-62	-415	2.86	274.5	0.0	784	1,201	-2				1,199	
66	72	0.07	576.7	7.8	41	-31	0				-31	
na	263	3.30	80.7	0.7	269	8	-2				6	
147	199	1.78	134.0	19.3	273	126		0			126	52
36	36	0.48	67.0	6.7	35	0	0				0	
241	301	1.84	263.0	12.4	506	242	-37				205	
699	760	0.64	1,006.2	26.1	660	-40	-72		-21		-133	-33
131	154	0.98	112.3	0.7	111	-28	-2				-30	14
	345 233 244 85 na -62 66 na 147 36 241 699	345 437 233 181 244 26 85 153 na 560 -62 -415 66 72 na 263 147 199 36 36 241 301 699 760	345 437 7.05 233 181 0.09 244 26 0.90 85 153 1.21 na 560 2.03 -62 -415 2.86 66 72 0.07 na 263 3.30 147 199 1.78 36 36 0.48 241 301 1.84 699 760 0.64	Spot EV Spot EV price shares 345 437 7.05 54.9 233 181 0.09 1,285.7 244 26 0.90 10.6 85 153 1.21 90.0 na 560 2.03 173.4 -62 -415 2.86 274.5 66 72 0.07 576.7 na 263 3.30 80.7 147 199 1.78 134.0 36 36 0.48 67.0 241 301 1.84 263.0 699 760 0.64 1,006.2	Spot EV Spot EV price shares deriv 345 437 7.05 54.9 1.2 233 181 0.09 1,285.7 133.4 244 26 0.90 10.6 0.2 85 153 1.21 90.0 0.0 na 560 2.03 173.4 1.4 -62 -415 2.86 274.5 0.0 66 72 0.07 576.7 7.8 na 263 3.30 80.7 0.7 147 199 1.78 134.0 19.3 36 36 0.48 67.0 6.7 241 301 1.84 263.0 12.4 699 760 0.64 1,006.2 26.1	Spot EV Spot EV price shares deriv Mkt Cap 345 437 7.05 54.9 1.2 395 233 181 0.09 1,285.7 133.4 128 244 26 0.90 10.6 0.2 10 85 153 1.21 90.0 0.0 109 na 560 2.03 173.4 1.4 355 -62 -415 2.86 274.5 0.0 784 66 72 0.07 576.7 7.8 41 na 263 3.30 80.7 0.7 269 147 199 1.78 134.0 19.3 273 36 36 0.48 67.0 6.7 35 241 301 1.84 263.0 12.4 506 699 760 0.64 1,006.2 26.1 660	Spot EV Spot EV price shares deriv Mkt Cap net debt 345 437 7.05 54.9 1.2 395 51 233 181 0.09 1,285.7 133.4 128 -36 244 26 0.90 10.6 0.2 10 -6 85 153 1.21 90.0 0.0 109 -43 na 560 2.03 173.4 1.4 355 -204 -62 -415 2.86 274.5 0.0 784 1,201 66 72 0.07 576.7 7.8 41 -31 na 263 3.30 80.7 0.7 269 8 147 199 1.78 134.0 19.3 273 126 36 36 0.48 67.0 6.7 35 0 241 301 1.84 263.0 12.4 506 242 <tr< td=""><td>Opot EV Spot EV price shares deriv Mkt Cap net debt leases 345 437 7.05 54.9 1.2 395 51 -43 233 181 0.09 1,285.7 133.4 128 -36 -14 244 26 0.90 10.6 0.2 10 -6 -10 85 153 1.21 90.0 0.0 109 -43 0 na 560 2.03 173.4 1.4 355 -204 -62 -415 2.86 274.5 0.0 784 1,201 -2 66 72 0.07 576.7 7.8 41 -31 0 na 263 3.30 80.7 0.7 269 8 -2 147 199 1.78 134.0 19.3 273 126 36 36 0.48 67.0 6.7 35 0 0</td><td>Spot EV Spot EV price shares deriv Mkt Cap net debt leases tax liab. 345 437 7.05 54.9 1.2 395 51 -43 233 181 0.09 1,285.7 133.4 128 -36 -14 244 26 0.90 10.6 0.2 10 -6 -10 85 153 1.21 90.0 0.0 109 -43 0 -1 na 560 2.03 173.4 1.4 355 -204 -2 -62 -415 2.86 274.5 0.0 784 1,201 -2 66 72 0.07 576.7 7.8 41 -31 0 na 263 3.30 80.7 0.7 269 8 -2 147 199 1.78 134.0 19.3 273 126 0 36 36 0.48 67.0<!--</td--><td>Opt EV Spot EV price shares deriv Mkt Cap net debt leases tax liab. Cons. 345 437 7.05 54.9 1.2 395 51 -43 -10 233 181 0.09 1,285.7 133.4 128 -36 -14 -2 244 26 0.90 10.6 0.2 10 -6 -10 -8 85 153 1.21 90.0 0.0 109 -43 0 -1 -10 na 560 2.03 173.4 1.4 355 -204 -2 -415 2.86 274.5 0.0 784 1,201 -2 -2 -62 -415 2.86 274.5 0.0 784 1,201 -2 -2 -66 72 0.07 576.7 7.8 41 -31 0 0 -3 -2 -43 1.4 -33 0 -0 -3 -2 -</td><td>Opt EV Spot EV price shares deriv Mkt Cap net debt leases tax liab. Cons. inflow 345 437 7.05 54.9 1.2 395 51 -43 -10 -10 233 181 0.09 1,285.7 133.4 128 -36 -14 -2 -2 244 26 0.90 10.6 0.2 10 -6 -10 -8 -10 -8 -10 -9 -43 0 -1<</td><td>Opt EV Spot EV price shares deriv Mkt Cap net debt leases tax liab. Cons. inflow BDND 345 437 7.05 54.9 1.2 395 51 -43 -10 -2 233 181 0.09 1,285.7 133.4 128 -36 -14 -2 -52 244 26 0.90 10.6 0.2 10 -6 -10 -2 -52 85 153 1.21 90.0 0.0 109 -43 0 -1 -44 na 560 2.03 173.4 1.4 355 -204 -2 -204 -62 -415 2.86 274.5 0.0 784 1,201 -2 1,199 66 72 0.07 576.7 7.8 41 -31 0 -2 -31 na 263 3.30 80.7 0.7 269 8 <t< td=""></t<></td></td></tr<>	Opot EV Spot EV price shares deriv Mkt Cap net debt leases 345 437 7.05 54.9 1.2 395 51 -43 233 181 0.09 1,285.7 133.4 128 -36 -14 244 26 0.90 10.6 0.2 10 -6 -10 85 153 1.21 90.0 0.0 109 -43 0 na 560 2.03 173.4 1.4 355 -204 -62 -415 2.86 274.5 0.0 784 1,201 -2 66 72 0.07 576.7 7.8 41 -31 0 na 263 3.30 80.7 0.7 269 8 -2 147 199 1.78 134.0 19.3 273 126 36 36 0.48 67.0 6.7 35 0 0	Spot EV Spot EV price shares deriv Mkt Cap net debt leases tax liab. 345 437 7.05 54.9 1.2 395 51 -43 233 181 0.09 1,285.7 133.4 128 -36 -14 244 26 0.90 10.6 0.2 10 -6 -10 85 153 1.21 90.0 0.0 109 -43 0 -1 na 560 2.03 173.4 1.4 355 -204 -2 -62 -415 2.86 274.5 0.0 784 1,201 -2 66 72 0.07 576.7 7.8 41 -31 0 na 263 3.30 80.7 0.7 269 8 -2 147 199 1.78 134.0 19.3 273 126 0 36 36 0.48 67.0 </td <td>Opt EV Spot EV price shares deriv Mkt Cap net debt leases tax liab. Cons. 345 437 7.05 54.9 1.2 395 51 -43 -10 233 181 0.09 1,285.7 133.4 128 -36 -14 -2 244 26 0.90 10.6 0.2 10 -6 -10 -8 85 153 1.21 90.0 0.0 109 -43 0 -1 -10 na 560 2.03 173.4 1.4 355 -204 -2 -415 2.86 274.5 0.0 784 1,201 -2 -2 -62 -415 2.86 274.5 0.0 784 1,201 -2 -2 -66 72 0.07 576.7 7.8 41 -31 0 0 -3 -2 -43 1.4 -33 0 -0 -3 -2 -</td> <td>Opt EV Spot EV price shares deriv Mkt Cap net debt leases tax liab. Cons. inflow 345 437 7.05 54.9 1.2 395 51 -43 -10 -10 233 181 0.09 1,285.7 133.4 128 -36 -14 -2 -2 244 26 0.90 10.6 0.2 10 -6 -10 -8 -10 -8 -10 -9 -43 0 -1<</td> <td>Opt EV Spot EV price shares deriv Mkt Cap net debt leases tax liab. Cons. inflow BDND 345 437 7.05 54.9 1.2 395 51 -43 -10 -2 233 181 0.09 1,285.7 133.4 128 -36 -14 -2 -52 244 26 0.90 10.6 0.2 10 -6 -10 -2 -52 85 153 1.21 90.0 0.0 109 -43 0 -1 -44 na 560 2.03 173.4 1.4 355 -204 -2 -204 -62 -415 2.86 274.5 0.0 784 1,201 -2 1,199 66 72 0.07 576.7 7.8 41 -31 0 -2 -31 na 263 3.30 80.7 0.7 269 8 <t< td=""></t<></td>	Opt EV Spot EV price shares deriv Mkt Cap net debt leases tax liab. Cons. 345 437 7.05 54.9 1.2 395 51 -43 -10 233 181 0.09 1,285.7 133.4 128 -36 -14 -2 244 26 0.90 10.6 0.2 10 -6 -10 -8 85 153 1.21 90.0 0.0 109 -43 0 -1 -10 na 560 2.03 173.4 1.4 355 -204 -2 -415 2.86 274.5 0.0 784 1,201 -2 -2 -62 -415 2.86 274.5 0.0 784 1,201 -2 -2 -66 72 0.07 576.7 7.8 41 -31 0 0 -3 -2 -43 1.4 -33 0 -0 -3 -2 -	Opt EV Spot EV price shares deriv Mkt Cap net debt leases tax liab. Cons. inflow 345 437 7.05 54.9 1.2 395 51 -43 -10 -10 233 181 0.09 1,285.7 133.4 128 -36 -14 -2 -2 244 26 0.90 10.6 0.2 10 -6 -10 -8 -10 -8 -10 -9 -43 0 -1<	Opt EV Spot EV price shares deriv Mkt Cap net debt leases tax liab. Cons. inflow BDND 345 437 7.05 54.9 1.2 395 51 -43 -10 -2 233 181 0.09 1,285.7 133.4 128 -36 -14 -2 -52 244 26 0.90 10.6 0.2 10 -6 -10 -2 -52 85 153 1.21 90.0 0.0 109 -43 0 -1 -44 na 560 2.03 173.4 1.4 355 -204 -2 -204 -62 -415 2.86 274.5 0.0 784 1,201 -2 1,199 66 72 0.07 576.7 7.8 41 -31 0 -2 -31 na 263 3.30 80.7 0.7 269 8 <t< td=""></t<>

Source: FactSet and company reports



Exhibit 7: Stock Performance

13-Ma y-25	<u>Sto</u>	ck Performa	ince
	Last	Last	Last
Ticker	30d	90d	12mo
US MSOs			
Ascend	28%	-6%	-72%
Ayr	84%	-43%	-89%
Cannabist	51%	-18%	-81%
Cansortium	-8%	-28%	-70%
Cresco	21%	-20%	-65%
Curaleaf	3%	-43%	-85%
4Front	-69%	-81%	-97%
GlassHouse	42%	4%	-35%
Gold Flora	#N/A	-30%	-85%
Grown Rogue	5%	-31%	-42%
Green Thumb	8%	-24%	-58%
iAnthus	-52%	-41%	-76%
Jushi	21%	-3%	-49%
Ma ri Me d	9%	-34%	-68%
Planet13	6%	-28%	-58%
Schwazze	na	-29%	-97%
StateHouse	na	na	-46%
Trulieve	27%	-7%	-63%
TerrAscend	40%	-42%	-78%
Verano	32%	-43%	-86%
Vext	-26%	-20%	-66%
Vireo Growth	0%	-30%	-29%
International			
InterCure	23%	-32%	-41%
Pharma Ci e lo	-32%	3%	105%

	<u>Sto</u>	ck Performa	<u>nce</u>
	Last	Last	Last
Ticker	30d	90d	12mo
Canadian LPs			
Aurora	18%	-21%	-22%
Avant	-8%	-23%	-63%
Auxly	12%	65%	47%
Ayurcann	2%	-39%	-41%
Cannara	-1%	8%	50%
Canopy	55%	-19%	-84%
Cronos	17%	4%	-26%
Decibel	22%	-11%	-37%
Entourage	0%	25%	-58%
High Tide	17%	-12%	4%
OGI	24%	-11%	-27%
Rubicon	-20%	11%	21%
SNDL	-3%	-27%	-43%
Tilray	-6%	-51%	-76%
VFF	40%	-10%	-44%
Tech			
LFLY	50%	15%	-84%
SBIG	63%	-1%	-52%
MAPS	8%	-13%	-2%
Vape parts			
GNLN	-98%	-100%	-100%
ISPR	-13%	-31%	-50%
SMORF	0%	2%	34%
TLLTF	36%	5%	-76%

	<u>St</u>	ock Performan	<u>ice</u>
	Last	Last	Last
Ticker	30d	90d	12mo
MJ Fincos			
AFCG	19%	-35%	-54%
IIPR	13%	-25%	-46%
NLCP	9%	-11%	-28%
SHFS	9%	-72%	-85%
LIEN	-7%	-14%	-12%
REFI	11%	-6%	-5%
Pix & Shovel			
AGFY	50%	28%	548%
GRWG	26%	-22%	-62%
HYFM	41%	-33%	-59%
SMG	11%	-16%	-17%
UGRO	-28%	-46%	-78%
CBD			
CVSI	-5%	-32%	-41%
CWEB	0%	-24%	-54%
LFID	-8%	19%	-69%
Index			
S&P 500	9%	-4%	12%
S&P 477	1%	-1%	8%
Nasdaq	13%	1%	33%
MSOS ETF	16%	-25%	-72%
YOLO ETF	17%	-18%	-53%
Simple Group Av	erages		
Large Canada	24%	-23%	-54%
Tier 1 MSOs	18%	-27%	-71%

Source: FactSet



Appendix III: Bio and Disclaimers



Analyst Bio

Pablo Zuanic is a well-known and highly rated equity analyst following the cannabis and psychedelics sector. Over the past five years he launched coverage of over 40 companies in the US, Canada, and overseas (MSOs, LPs, CBD, ancillary, psychedelics), kept close track of sectoral trends, and followed the reform process in the US and elsewhere. His firm Zuanic & Associates publishes equity research on the cannabis and psychedelics sectors, both from a macro/sectoral level in a thematic manner, as well as specific reports on listed stocks. The research service is aimed at institutional investors and corporations. The firm is also available for short-term consulting and research advisory projects. At various points in his career, Pablo was II ranked and called as expert witness in industry investigations. He has a deep global background having covered stocks over the past 20 years in the US, Europe, Latin America, and Asia, across consumer sub sectors. Prior employers include JP Morgan, Barings, and Cantor Fitzgerald. An MBA graduate of Harvard Business School, he started his career as a management consultant, which brings a strategic mindset to his approach to equity research. *Pablo Zuanic can be contacted via the company's portal www.zuanicassociates.com; via email pablo.zuanic@zuanicgroup.com; or via X @4200dysseus*.



Disclosures and Disclaimers

About the firm: Zuanic & Associates is a domestic limited liability company (LLC) registered in the state of New Jersey. The company's registered address is Five Greentree Centre, 525 Route 73, N Suite 104, Marlton, New Jersey 08053, USA. Pablo Zuanic is the registered agent. The firm publishes equity research on selected stocks in the cannabis and psychedelics sector, as well as thematic macro industry notes. The firm also provides consulting and advisory services. Potential conflicts of interest are duly reflected in the respective specific company reports.

Analyst Certification: The publishing analyst, whose name appears on the front page of this report, certifies that the views expressed in this independent research report accurately reflects his personal views about the subject securities or issuers discussed in this report. His opinions and estimates are based on his best judgement at the time of publication and are subject to change without notice. As per the company's policy, the author of this report does not own shares in any company he covers.

Other: This report is for use by professional and or institutional investors only, and it is deemed impersonal investment advice, published on a bona fide and regular basis. This report is for informational purposes only and is based on publicly available data believed to be reliable, but no representation is made whether such data are accurate or complete. As such, this report should not be regarded by its recipients as a substitute for obtaining independent investment advice and/or exercise of their own judgement. When making an investment decision this information should be viewed as just one factor in the investment decision process. Neither the publishing analyst, nor any of the company's officers and directors, accept any liability for any loss or damage arising out of the use of all or any part of the analyst's research.

Risks: The financial instruments mentioned in this report may not be suitable for all investors and investors must make their own investment decisions based on their specific investment objectives. Past performance should not be taken as an indication or guarantee of future performance. The price, value of and income from, any of the financial instruments featured in this report can rise as well as fall and be affected by changes in political, financial, and economic factors. If a financial instrument is denominated in a currency other than the investor's currency, a change in exchange rates may adversely affect the price or value of, or income derived from, the financial instrument, and such investors effectively assume currency risk.

Disclosure: Zuanic & Associates offers advisory and research services, and it also organizes investor events and conferences. The firm is often engaged by various operators in the cannabis industry (both plant touching companies and those providing services, private and public, in North America and overseas) on an ongoing or ad hoc basis. The company discussed in this report is a paying customer of the services provided by the firm.

Copyright: No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.